SmartTab will present at the 2021 Crohn’s & Colitis Congress®, on January 21-24, 2021. We are thrilled to be selected by the Crohn’s & Colitis Foundation and the American Gastroenterological Association to present our abstract: Advancing High Tech Drug Delivery Systems for the Treatment of Crohn’s Disease.
The congress is virtual this year and is an incredible opportunity for IBD professionals from around the world to connect.
SmartTab will discuss the success of our TargetTab during animal testing. Recently we completed a Pharmacokinetic Pre-Clinical Animal study using 50 lb Yorkshire swine. The TargetTab capsules were manufactured with the known active ingredient of caffeine. Findings shed light on how SmartTab’s drug delivery system uses precise location targeting and delivery to reduce side effect risks while growing dosage effectiveness in the treatment of Crohn’s Disease.
We hope that you attend the 2021 Crohn’s & Colitis Congress®, to explore what these findings mean for the future of SmartTab and targeted drug delivery. Our recent Pre-clinical Animal Studies hold the potential to generate further advancement in high-tech drug delivery systems that are going to change the world.
SmartTab’s presenter at the virtual conference will be Dr. Douglas Miller, our Chief Technology Officer. He has over 25 years of experience in the medical device field, including academic research, multinational corporate R&D, as well as playing key roles in three previous start-ups. With nine patents in the biomedical field, and as a published author with a BS in Electrical Engineering and an MS & Ph.D. in Electrical/Biomedical Engineering, you don’t want to miss his groundbreaking presentation.
We are preparing to reapply this technology in the form of an injection capsule—exciting updates are coming soon! Subscribe to our newsletter to stay up to date.